Sofosbuvir for COVID-19 infection: A potential candidate.

Gupta, Rohit; Dhamija, Puneet

Gupta, Rohit; Dhamija, Puneet.

Gupta R; Department of Gastroenterology and Pharmacology, AIIMS, Rishikesh, Uttarakhand, India.
Dhamija P; Department of Gastroenterology and Pharmacology, AIIMS, Rishikesh, Uttarakhand, India.

Indian J Pharmacol ; 52(3): 232-233, 2020.

Article in English | MEDLINE | ID: covidwho-740522

Subject(s)

Antiviral Agents/therapeutic use; Betacoronavirus/drug effects; Coronavirus Infections/drug therapy; Pneumonia, Viral/drug therapy; Sofosbuvir/therapeutic use; Antiviral Agents/adverse effects; Betacoronavirus/pathogenicity; COVID-19; Coronavirus Infections/diagnosis; Coronavirus Infections/virology; Host Microbial Interactions; Humans; Pandemics; Pneumonia, Viral/diagnosis; Pneumonia, Viral/virology; SARS-CoV-2; Sofosbuvir/adverse effects; Treatment Outcome; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Sofosbuvir / Betacoronavirus Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Indian J Pharmacol Year: 2020 Document Type: Article Affiliation country: Ijp.IJP_675_20

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google